Mereo BioPharma Group plc announced financial results for Q2 2025, with cash of $56.1 million supporting operations into 2027. Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta are expected by year-end 2025. The Orbit study, led by Ultragenyx, showed an acceptable safety profile. Mereo continues discussions for alvelestat. R&D expenses increased to $5.4 million, G&A expenses decreased to $5.5 million in Q2 2025. Net loss was $14.6 million. Cash and cash equivalents were $56.1 million as of June 30, 2025. Mereo expects to fund operations through 2027. Total shares issued were 795,001,444 as of June 30, 2025.

Read more at GlobeNewswire: Mereo BioPharma Reports Second Quarter 2025 Financial